Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies

Am J Respir Crit Care Med. 2019 Jul 15;200(2):133-139. doi: 10.1164/rccm.201903-0592PP.
No abstract available

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Clinical Trials as Topic*
  • Drug Approval
  • Drug Development
  • Drug Interactions
  • Drug Therapy, Combination
  • Humans
  • Idiopathic Pulmonary Fibrosis / drug therapy*
  • Idiopathic Pulmonary Fibrosis / genetics
  • Idiopathic Pulmonary Fibrosis / physiopathology
  • Indoles / therapeutic use
  • Patient Outcome Assessment
  • Protein Kinase Inhibitors / therapeutic use
  • Pyridones / therapeutic use
  • Quality of Life
  • Standard of Care
  • Vital Capacity
  • Walk Test

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Indoles
  • Protein Kinase Inhibitors
  • Pyridones
  • pirfenidone
  • nintedanib